Search Results

Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of

pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board. She codirected the AACR

. 18. Lyman GH Kuderer NM . Economics of hematopoietic growth factors . In: Morstyn G, Foote M, Lieschke GJ, eds. Cancer Drug Discovery and Development . Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics

adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board. She codirected the AACR/ASCO Methods in Clinical

, MD Margaret Tempero, MD, is a Professor of Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics

revolution, and the experts on our Guideline Panels are the ideal physician-scientists to offer ever-changing guidance in this exciting new world of oncology therapeutics. It has been my pleasure to serve as Chair of the Board of NCCN for these past few

JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer

and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently

and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently

Tempero, MD, is a Professor of Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has